Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOL100
- Development stage
- Unknown
- Lead developer
- Shine-On Biomedical
- Modality
- Cell Therapies
01
Overview
SOL100 is an experimental therapeutic candidate developed by Shine-On BioMedical, utilizing a technology platform focused on therapeutic immune depletion and rejuvenation. It is designed to serve as a supportive or preparatory treatment in the context of CAR-T cell therapy or as part of a "factory of biologics" platform. The mechanism involves resetting or improving immune function, potentially by clearing exhausted or dysfunctional immune cells to create a more favorable environment for the expansion and activity of engineered T cells or the production of biologics. As of early 2024, SOL100 is in the preclinical to Phase 1 stage of development.
02
Targets
HLA-G (Human leukocyte antigen G)
Beyond the preview
Go deeper on SOL100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOL100.